Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
v2.4.0.6
Subsequent Events
9 Months Ended
Sep. 30, 2012
Subsequent Events [Abstract]  
Subsequent Events

6. Subsequent Events   On October 1, 2012 the Company entered into a services agreement with a public relations and investor relations firm. Under the agreement, the Company will issue 50,000 shares of common stock in lieu of cash for services to be rendered over the next five months. Upon expiration of the initial term, a monthly cash retainer of up to $10,000 will be incurred. Additionally, up to 250,000 warrants may be issued with exercise prices varying between $1.25 and $2.75 over the next twelve months upon the achievement of time based objectives.
       
      On October 9, 2012, the Company filed with the Secretary of State of the State of Delaware an Amendment to the Certificate of Incorporation of Q Therapeutics, Inc. therein changing the name of Q Therapeutics, Inc. to Q Therapeutic Products, Inc., effective immediately.
       
      On October 16, 2012, the Company entered into an agreement with a financial advisor and placement agent in connections with possible capital raising transactions.  Under the agreement, the financial advisor will receive a 7% commission on offering proceeds and five year warrants to purchase common stock valued at 10% of the common stock sold. The agreement is expected to continue for a period of at least six months.
       
      On October 30, 2012, the Company filed with the Secretary of State of the State of Delaware an Amendment to the Certificate of Incorporation of Q Holdings, Inc. therein changing the name of Q Holdings, Inc. to Q Therapeutics, Inc., effective December 10, 2012.